Summary of the treatment of newly diagnosed patients
| . | n (%) . |
|---|---|
| Induction | |
| CyBorD | 42 (26) |
| RVD | 80 (50) |
| Others | 37 (23) |
| ASCT, yes | 136 (86) |
| Double ASCT, yes | 5 (4) |
| Consolidation post ASCT, yes | 17 (11) |
| Maintenance, yes | 135 (85) |
| Type of maintenance | |
| Lenalidomide | 69 (51) |
| Proteasome inhibitors | 20 (15) |
| IMiD+ proteasome inhibitors | 29 (22) |
| Others | 16 (12) |
| . | n (%) . |
|---|---|
| Induction | |
| CyBorD | 42 (26) |
| RVD | 80 (50) |
| Others | 37 (23) |
| ASCT, yes | 136 (86) |
| Double ASCT, yes | 5 (4) |
| Consolidation post ASCT, yes | 17 (11) |
| Maintenance, yes | 135 (85) |
| Type of maintenance | |
| Lenalidomide | 69 (51) |
| Proteasome inhibitors | 20 (15) |
| IMiD+ proteasome inhibitors | 29 (22) |
| Others | 16 (12) |
ASCT, autologous stem cell transplantation; CyBorD, bortezomib, cyclophosphamide, dexamethasone; IMiD, immunomodulatory drugs; RVD, bortezomib, revlimid, dexamethasone.